Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: AdvancedAdvT buys into M&C Saatchi

Wed, 05th Jan 2022 10:50

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

M&C Saatchi PLC, up 15% at 192.00 pence, 12-month range 84.75p-200.00p. Main Market-listed acquisition vehicle AdvancedAdvT Ltd says it has purchased 12.0 million shares in the London-based advertising agency, at GBP2.00 each. The buy represents a 9.8% stake. AdvancedAdvT sees M&C as a "good investment opportunity". Shares hit this 12-month high on Wednesday. AdvancedAdvT shares are 1.4% higher.

----------

Concurrent Technologies PLC, up 8.3% at 86.60 pence, 12-month range 71.00p-113.00p. The embedded computer products manufacturer expects its 2021 results to beat market forecasts, shaking off global supply chain challenges. It also expects to pay a final dividend, to go with its 1.15p interim payout. Its total 2020 dividend was 2.55p.

----------

AIM - LOSERS

----------

Blue Star Capital PLC, down 5.0% at 0.52p, 12-month range 0.11p-0.58p. The investor, with a focus on esports, payments, technology, notes is recent share price rise, but says it is "not aware of a reason" for the buying action. Shares surged 38% on Tuesday.

----------

ValiRx PLC, down 13% at 33.42p, 12-month range 17.26p-65.00p. The Nuneaton, Warwickshire-based cancer and women's health treatment developer inks a service agreement with TheoremRx to support the next clinical trail of VAL201, a potential treatment for prostate cancer. ValiRx will work as a consultant to TheoremRx. In return, ValiRx says it will receive a monthly consultancy fee until the agreement is terminated. Despite the deal, shares are still down, though this is in the wake of a 4.8% gain on Tuesday and a 19% rise in the final two weeks of December.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
4 May 2020 16:10

ValiRx Competes GBP1.2 Million Placing To Fund VAL201 Trial Close-Out

ValiRx Competes GBP1.2 Million Placing To Fund VAL201 Trial Close-Out

Read more
4 May 2020 14:26

ValiRx shores up capital position with ?1.17m fundraise

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced a conditional fundraise through the conditional issue of 18,069,467 new ordinary shares on Monday, to raise ?1.17m.

Read more
1 May 2020 14:57

UK EXECUTIVE CHANGE SUMMARY: Immedia Picks COO Penney As Interim CEO

UK EXECUTIVE CHANGE SUMMARY: Immedia Picks COO Penney As Interim CEO

Read more
1 May 2020 14:33

ValiRx signs VAL301 deal with Japanese firm

(Sharecast News) - Clinical-stage biotechnology company ValiRx has signed an agreement with an unnamed global Japanese pharmaceutical company to evaluate its therapeutic, VAL301, in order to contemplate a potential future license for its use in the treatment of endometriosis.

Read more
1 May 2020 14:23

ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm

ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm

Read more
1 May 2020 10:42

UK WINNERS & LOSERS SUMMARY: RBS Rises Despite Profit Sinking

UK WINNERS & LOSERS SUMMARY: RBS Rises Despite Profit Sinking

Read more
29 Apr 2020 18:19

ValiRx Confirms JV Talks For Non-Core Intellectual Property

ValiRx Confirms JV Talks For Non-Core Intellectual Property

Read more
14 Apr 2020 14:51

UK EXECUTIVE CHANGE SUMMARY: Harvest Minerals CFO Leaves To Save Cost

UK EXECUTIVE CHANGE SUMMARY: Harvest Minerals CFO Leaves To Save Cost

Read more
7 Apr 2020 16:10

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Apr 2020 13:57

ValiRx raises ?0.2m through placing with new investors

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that it has conditionally raised ?0.2m gross through the issue of 5,714,288 new ordinary shares at a post-reorganisation price of 3.5p each, with new investors.

Read more
1 Apr 2020 12:12

ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position

ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position

Read more
30 Mar 2020 16:41

ValiRx "Critically Short" Of Working Capital, In Funding Discussions

ValiRx "Critically Short" Of Working Capital, In Funding Discussions

Read more
10 Mar 2020 11:42

ValiRx Still Faces Going Out Of Business; Proposes New Share Plan

ValiRx Still Faces Going Out Of Business; Proposes New Share Plan

Read more
4 Mar 2020 17:25

ValiRx Investors Seek Removal Of Directors Morris And Vainikka

ValiRx Investors Seek Removal Of Directors Morris And Vainikka

Read more
17 Feb 2020 12:48

ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation

ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.